IMMUNOCORE HOLDINGS PLC

Shareholders of Immunocore Holdings plc

Immunocore Holdings plc’s ordinary shares trade on Nasdaq via American Depositary Shares (ticker IMCR), and its UK share register is held predominantly through custodial nominee accounts rather than by named beneficial owners. Per Companies House-sourced share register data verified 17 September 2026, the largest registered holder is National City Nominees Limited, with 43,861,622 ordinary shares (approximately 83.5% of the class), followed by Immunocore Nominees Limited with 5,793,500 deferred shares (approximately 11.0%) and Chase Nominees Limited with 2,900,000 ordinary shares (approximately 5.5%). These nominee holdings reflect the depositary and custodian structure used for Nasdaq-listed ADSs and are not the underlying beneficial owners.

Beneficial ownership of 5% or more of Immunocore Holdings plc’s shares (including in ADS form) is separately disclosed to the U.S. Securities and Exchange Commission under Schedule 13D/13G. PRIMECAP Management Co. reported beneficial ownership of approximately 7.51% (3,772,234 shares) as of 30 June 2025. Vestal Point Capital, LP filed a Schedule 13G on 15 May 2026 disclosing approximately 5.5% (2,766,868 ADSs), later amended to approximately 3.5% (1,800,000 ADSs) as of 30 June 2026. General Atlantic-affiliated entities, which reported 11.5% in a July 2022 Schedule 13D, had reduced their stake to approximately 3.5% by a 2024 Schedule 13D/A, placing them below the 5% disclosure threshold.

Ultimate beneficial ownership

Immunocore Holdings plc’s Companies House Persons with Significant Control (PSC) register states that, since 6 January 2022, the company is exempt from PSC-reporting requirements because its voting shares are admitted to trading on a market specified in the Register of People with Significant Control Regulations 2016. The current active statement, notified 22 January 2021, records that the company knows of no registrable person or registrable relevant legal entity. A prior PSC entry for Sir John Irving Bell (75%+ ownership of shares and voting rights, right to appoint or remove directors) is recorded as ceased on 22 January 2021, coinciding with the group’s pre-IPO reorganisation. No current individual UBO is identified on the public record.

Data availability

Shareholder disclosure for Immunocore Holdings plc is major shareholders only: the UK register lists custodial nominees rather than beneficial owners, and PSC information is not required because of the company’s Nasdaq listing exemption. SEC Schedule 13D/13G filings give partial visibility into institutional holders that have crossed the 5% threshold but do not capture the full shareholder base.

Sources

• Companies House, Persons with Significant Control, company 13119746 — https://find-and-update.company-information.service.gov.uk/company/13119746/persons-with-significant-control (retrieved 18 September 2026)
• Internal share register data sourced from Companies House filings (verified 17 September 2026)
• SEC Schedule 13G, PRIMECAP Management Co. — https://www.sec.gov/Archives/edgar/data/0001671927/000108514625005193/primary_doc.xml (retrieved 18 September 2026)
• SEC Schedule 13G / 13G-A, Vestal Point Capital, LP — https://www.sec.gov/Archives/edgar/data/0001671927/000090266426002542/primary_doc.xml (retrieved 18 September 2026)
• SEC Schedule 13D/A, General Atlantic entities — https://www.sec.gov/Archives/edgar/data/1671927/000095014224000652/eh240456101_13da6-imcr.htm (retrieved 18 September 2026)

Directors and officers of Immunocore Holdings plc

Companies House records eight active officers and three resigned officers for Immunocore Holdings plc as of 18 September 2026. The current board comprises seven directors — Sir John Irving Bell (appointed 7 January 2021), Kristine Peterson and Bahija Jallal (both appointed 22 January 2021), Roy Steven Herbst (appointed 28 January 2021), Sir Peter John Ratcliffe (appointed 22 January 2021), Siddharth Kaul (appointed 8 June 2022) and William Pao (appointed 25 February 2025) — together with company secretary Lily Margaret Hepworth (appointed 7 January 2021). All active officers list a correspondence address at the company’s registered office, 92 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY.

Recent officer changes

• Ranjeev Krishana, Director, resigned 26 November 2025 (appointed 28 May 2024) — Companies House.
• Robert Perez, Director, resigned 16 September 2025 (appointed 22 January 2021) — Companies House.
• William Pao, Director, appointed 25 February 2025 — Companies House.

Data availability

Companies House discloses nationality and country of residence for UK-registered company directors, and these are reported here exactly as filed rather than inferred from name or address: Sir John Irving Bell (British, Canadian; resident United Kingdom), Sir Peter John Ratcliffe (British; resident United Kingdom), Kristine Peterson, Roy Steven Herbst, Siddharth Kaul and William Pao (American; resident United States), and Bahija Jallal (American, Moroccan; resident United States). The shared correspondence address of the registered office is a service address only and is not evidence of nationality or residence. The company secretary’s nationality is not published on the public register.

Sources

• Companies House, Officers, company 13119746 — https://find-and-update.company-information.service.gov.uk/company/13119746/officers (retrieved 18 September 2026)

Group structure of Immunocore Holdings plc

Immunocore Holdings plc is the top-level, Nasdaq-listed holding company of the Immunocore group and has no identified corporate parent; it was incorporated on 7 January 2021 specifically to become the holding company of Immunocore Limited ahead of the group’s 2021 IPO and Nasdaq listing. According to the company’s Form 10-K for the year ended 31 December 2025 (filed with the SEC in 2026), Immunocore Holdings plc has six wholly owned subsidiaries spanning the United Kingdom, the United States, Ireland and Switzerland. This is presented as a flat, verified subsidiary list rather than a multi-tier ownership chain, as the SEC exhibit does not itself specify intermediate ownership tiers.

Verified corporate relationships

Data availability

Corporate-linkage information for Immunocore Holdings plc is full at the subsidiary level: the group’s six subsidiaries are independently confirmed by the company’s SEC Exhibit 21.1 filing, which describes them as wholly owned. Immunocore Limited’s registration number and active status were independently confirmed against Companies House. The US, Irish and Swiss registration numbers and the Companies House-only entity, Immunocore Nominees Limited, were not independently re-verified against their respective registries in this review and are marked accordingly rather than presented as confirmed.

Sources

• SEC EDGAR, Immunocore Holdings plc, Exhibit 21.1, Subsidiaries of Registrant, Form 10-K for FY2025 — https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/subsidiariesoftheregistran.htm (retrieved 18 September 2026)
• Companies House, IMMUNOCORE LIMITED, company 06456207 — https://find-and-update.company-information.service.gov.uk/company/06456207 (retrieved 18 September 2026)
• Companies House, IMMUNOCORE HOLDINGS PLC, company 13119746 — https://find-and-update.company-information.service.gov.uk/company/13119746 (retrieved 18 September 2026)